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Abstract 
Lymphoedema Network Wales has focused on maximising the impact of its service through the 
effective use of available resources to ensure high quality and consistent care for people with 
lymphoedema across Wales. The aim of this evaluation was to estimate the economic impact of 
a National lymphoedema service on the NHS Wales budget. Work was undertaken to determine 
the care pathway within Lymphoedema Network Wales and develop a hypothetical ‘world 
without’ the service as a comparator. The four groups of patients that made up the pathways 
were ‘Group 0 At Risk’, ‘Group 1-2 uncomplicated lymphoedema’, ‘Group 3 
Complicated/Complex’ and ‘Group 4 Palliative Care’. Overall resource utilisation between the six 
month ‘pre’ and six month ‘post entry’ indicated that there were significant resource reductions 
to be seen after lymphoedema service entry for all patients in each group. This evaluation 
provides estimates that suggest that the service is likely to be cost saving when people with 
lymphoedema are managed within Lymphoedema Network Wales rather than in a ‘world 
without’ the service. 
 
Introduction  
Lymphoedema is a long-term (chronic) condition that causes swelling in the body’s tissues due 
to lymphatic system failure. It can affect any part of the body, but usually develops in the arms 
or legs. (NHS UK 2017).   It is an incurable condition and requires lifelong management (Moffatt, 
et al., 2003). Lymphoedema can affect people of all ages and can occur in limbs, the head and 
neck, trunk or genital area. It may not become apparent for some time after trauma or surgery, 
and patients remain at risk of developing lymphoedema for life (Morgan, Franks & Moffatt, 
2005). 
 
 It has a profound effect on people’s quality of life (QoL) and their ability to engage in normal 
daily activities (Ridner, 2009). It has a significant impact on NHS resources as patients have a 
number of hospital admissions for cellulitis infections related to their lymphoedema (Moffat, et 
al., 2003).  Evidence supplied by Lymphoedema Network Wales indicates that the prevalence 
rate for the condition in Wales is currently more than 5.49 per 1,000 populations, with a 
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prevalent population of over 17,000 people with the condition receiving treatment and signs 
that these numbers are increasing (Thomas & Morgan, 2017) .  
 
The 2009 Strategy for Lymphoedema in Wales set out key actions for local health boards in 
delivering services; with emphasis on a whole system approach to ensure care can be provided 
most appropriately and efficiently. Up until January 2012, there was wide variation in the 
organisation and delivery of lymphoedema services across Wales. Some trusts had 
commissioned full lymphoedema services; others offered services that can only be accessed by 
cancer patients. Some individual health boards did not provide any services. Since January 2012, 
six new services were developed in health boards and localities (Bridgend, Ceredigion, Cwm Taf, 
Aneurin Bevan, Cardiff & Vale and Powys), based on the 2009 strategy. The current caseload is 
increasing per quarter with many patients giving detailed histories of their long wait for 
adequate lymphoedema services which has affected their QoL.   
 
Evaluation aim and objectives 
The aim of this evaluation was to estimate the economic (cost) impact of Lymphoedema 
Network Wales on the NHS Wales budget. The objectives were to:   
 Quantify the likely cost burden associated with lymphoedema in Wales. 
 Assess the wider costs to patients and families resulting from lymphoedema. 
 Estimate the financial benefits associated with the services provided in Wales. 
 
Methods  
The Lymphoedema Network Wales team administered a resource utilisation questionnaire 
(RUQ) that was created by the research team. The RUQ was developed reflecting service usage 
across primary care (e.g. GP visits, community care), secondary care, personal social services, 
and wider usage such as community pharmacist services. Two questions were added to give a 
summary of patient satisfaction to provide an indication of a patient- reported outcome 
associated with the service. We also consulted relevant guidelines on the management of 
lymphoedema from the British Lymphoedema Society (British Lymphology Society, 2001), the 
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National Lymphoedema Framework (National Framework, 2006) and International 
Lymphoedema Society (International Society of Lymphology, 2003). 
Due to the absence of a ‘world without’ the service comparator for the evaluation (as the 
service is fully established in Wales with no historical control available); the questionnaire was 
administered in two parts. The first part asked the selected patients for their resource utilisation 
six months prior to entering the Lymphoedema Service. The second part asked for their 
resource utilisation six months post entering the Lymphoedema Service. This enabled a pre/post 
estimation to be made for these patients in order to generate a hypothetical ‘world without’ 
comparator.   Participants completed the questionnaires using recall, but were then verified via 
their case notes and electronic medical data systems. Participants were purposively recruited 
from each of the seven lymphoedema services across Wales by the clinical lead specialists. The 
patients were asked to contribute in a route clinical lymphoedema assessment cross sectionally 
across Wales in the second week in January 2015. Each patient that was seen was asked if they 
wanted to contribute with a maximum of seven participants from each. All data were fully 
anonymised prior to analysis and ethical approval was granted from both Abertawe Bro 
Morgannwg University Health Board (ABMUHB) and Swansea University for analysis of the data. 
Development of Model Structure 
The design and structure of the lymphoedema service costing model was based on several 
inputs, each informed by the patient related information obtained from the lymphoedema 
service clinical lead interviews from the UHBs and the RUQs administered to patients. Also, 
based on information from the clinical leads’, estimated resource utilisation for these groups, as 
well as referral and caseload rates, were developed into four comparator group ‘types’ to 
compare with the baseline cost. These were: 
 ‘Group 0 At Risk’ – 11% of annual caseload,  
 ‘Group 1-2 Uncomplicated’ – 44% of annual caseload,  
 ‘Group 3 Complicates/Complex’ – 40% of annual caseload and  
 ‘Group 4 Palliative Care’ – 5% of annual caseload 
 
Finally, the four cost inputs were combined with the total ‘per UHB Lymphoedema Service’ staff 
costs to illustrate a ‘per UHB’ ‘cost’, as well as a ‘National Wales Lymphodema Service’ cost. 
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Data inputs 
The costing model was constructed based on information provided by Lymphoedema Network 
Wales information garnered from the fifty patient RUQs. The model uses ’current’ resource 
utilisation costs (PSSRU 2013) combined with the caseload numbers for each Health Board and 
the % of those patients attributed to each of the four groups. This information was again 
provided by Lymphoedema Network Wales. The overall yearly running costs of each individual 
health board service were input into the model to create an overall ‘All-Wales’ running cost. 
These data was compiled by adding up the number of staff in each centre by their grade band 
and FTE equivalent. 
To establish a ‘base case’ scenario that represented a ‘world without’ service comparison the 
RUQ was used to collect service user data from the fifty patients in lymphoedema services 
across Wales. The total cost of the 50 patient’s utilisation in primary and secondary care was 
£242,944. This equates to £4,859 per person in the baseline target group. Due to time and 
resource constraints, this does not include medication and/or appliance costs (such as garments 
or dressings). However further studies by the authors have illustrated significant cost savings in 
dressings with lymphoedema collaboration (Thomas & Morgan, 2017).  
Results 
Resource utilisation 
The mean resource utilisation for each category is shown in Table 1. The overall cost savings and 
resource utilisation between the six month ‘pre lymphoedema service entry’ and the six month 
‘post’ utilisation for the 50 patients is highlighted. There were significant savings to be seen, in 
particular GP Surgery Visits (£8,944), GP Home visits (£6,490), Practice Nurse appointments 
(£27,136), District Nurse calls (£51,380), Care Assistants (£15,270) and episodes of Cellulitis 
(£6,148). There was an overall saving of £132,104 across the 33 resource items analysed giving a 
mean overall per patient saving of £2,642.   
Table 1. Selected differences in resource utilisation 
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 Resource Pre 
Lymphoedema Service 
involvement 
Cost 
 Resource- Post 
Lymphoedema Service 
Involvement 
Cost 
Cost 
Difference 
Baseline GP Surgery £15,136 Six Months GP Surgery £6,192 -£8,944 
Baseline GP Home £8,470 Six Months GP Home £1,980 -£6,490 
Baseline District Nurse 
Home £71,540 
Six Months District Nurse 
Home £20,160 -£51,380 
Baseline Care Assistant £39,150 Six Months Care Assistant £23,880 £15,270 
Baseline Cellulitis £8,120 Six Months Cellulitis £1,972 -£6,148 
Costing model 
The base case results of the six month resource utilisation for the fifty patients before entering a 
lymphoedema service was £4,859 However, this is for six months so to extrapolate to an annual 
cost, this has been multiplied by two to get £9,718.  
When the pathway costs are combined and compared with the individual running costs of each 
of the lymphoedema groups it showed cost savings (see Table 2). The population of the active 
lymphoedema case load in 2015 was 9225 patients in Wales. Thus the lymphoedema groups 
were populated with percentages provided by Lymphoedema Network Wales as was discussed 
previously.  Estimated annual savings of £8,590,100 are seen for the Group 0 patients. Savings of 
£34,147,036 are seen for the Group 1 – 2 patients. An estimated £21,673,683 savings compared 
with the ‘world without’ the service estimates are seen for Group 3 and an estimated £270,553 
savings for Group 4 patients.  
Table 2 Lymphoedema Service Pathway results (All-Wales) 
Group 0 at risk total per person cost  £903 
Population 1015 (11%)  
Total estimated resource utilisation Cost  £916,053 
Intervention Cost £356,012 
Overall Cost £1,272,065 
Estimated No pathway cost £9,862,166 
Cost Savings  £8,590,100 
Group 1-2 uncomplicated oedema total per person cost  £1,218 
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Population 4059 (44%) 
Total estimated resource utilisation Cost  £4,945,616 
Intervention Cost £356,012 
Overall Cost £5,301,628 
Estimated No pathway cost £39,448,664 
Cost Savings £34,147,036 
Group 3 complicated complex total per person cost  £3,748 
Population 3690 (40%) 
Total estimated resource utilisation Cost  £13,832,726 
Intervention Cost £356,012 
Overall Cost £14,188,739 
Estimated No pathway cost £35,862,422 
Cost Savings £21,673,683 
Group 4 Palliative care total per person cost  £8,360 
Population 461 (5%) 
Total estimated resource utilisation Cost  £3,856,237 
Intervention Cost £356,012 
Overall Cost £4,212,250 
Estimated No pathway cost £4,482,803 
Cost Savings £270,553 
 
Summary of findings 
The potential costs associated with lymphoedema and its management in Wales are 
considerable. Our study of fifty Lymphoedema Network Wales patients’ six months prior to their 
entry to the lymphoedema service resource utilisation shows a mean cost per patient cost of 
£4,859 for the six months or £9,718 as an annual estimate.  
When the mean cost per patient is multiplied by the lymphoedema service’ annual active 
caseload (based in 2015) of 9,226, the potential costs equate to an estimated £89,656,054 for 
lymphoedema management in a ‘world without’ the service – i.e. if they were not supported by 
the Lymphoedema Network Wales service.  However, caution needs to be exercised in this 
estimation as multiplying these results to the current cases are a simple extrapolation.    
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The cost estimates indicated above are estimates based on an NHS perspective as the data was 
not sufficient to allow any reliable assessment of the wider societal costs of lymphoedema. The 
debilitating and life limiting nature of lymphoedema suggest the wider societal costs are 
considerable if family and friends care burden is taken into account. This combined with losses 
to productivity; intangible costs linked to health-related QoL issues make the overall societal 
cost burden of lymphoedema extensive and an important issue for future consideration.   
The six month estimates of ‘post-entry’ Lymphoedema service utilisation mean per patient cost 
of £2,217 indicates an overall estimated potential saving of £2,642 per patient compared with 
the pre service entry estimates. If these estimates are extrapolated to the caseload of 9226, in a 
lymphoedema service indicates an annual resource utilisation of £40,904,394, which when 
compared with the ‘world without’ the service suggests an annual saving to NHS Wales of 
£48,751,660 (‘pre’ service £89,656,054 – ‘post’ service £40,904,394).   
Discussion 
This evaluation of Lymphoedema Network Wales indicates that - compared to a ‘world without’ 
lymphoedema care, the service is delivering efficiencies to the NHS, particularly in terms of 
primary health care resources utilised. Primary care savings are seen for visits to Practice 
Nurses, District Nurses and Physiotherapists and when these are formally analysed in a costing 
model, these appear to be the main drivers of cost savings. However, caution must be given to 
the moderate-high uncertainty in these savings being realised given the threshold analysis 
undertaken, especially for Group 4 (palliative) patients.  This small study suggests an immediate 
need to prospectively evaluate lymphoedema services over a longer period of time; and 
consider in-depth different models of care delivery across Wales to develop understanding of 
what elements drive efficiencies. This evaluation has focused on the health care resources used 
and related cost rather than undertaking a full economic analysis to fully compare the costs of 
delivering Lymphoedema Network Wales against the change in health benefits, particularly in 
the translation of these benefits to patient outcomes such as QoL.   
Limitations 
There are several key limitations of the study that need to be acknowledged. This study is an 
examination of the incremental costs rather than a full economic evaluation i.e. where 
incremental costs are compared against incremental outcomes.  Thus, this only informs part of 
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the picture about the potential benefits and value of the lymphoedema service.  There has been 
a small qualitative study (Watts & Davies, 2016) but no formal assessment of the service with 
regard to health benefits and the value placed on these benefits for patients.   
The sensitivity analysis suggests that there is considerable uncertainty around our estimates.  
The threshold analysis also indicates uncertainty in our findings and suggests some of the 
findings are not plausible when caseload numbers and costs of services are varied.  The lack of 
any formal outcome analysis and full economic analysis (e.g. to derive a cost per quality 
adjusted life year) in this evaluation means that ‘value for money’ estimates for the service, in 
line with NICE recommendations (£20,000 - £30,000 cost per QALY threshold) were not possible 
and need to be considered for future evaluations.  
The main cost drivers compared with the ‘world without’ the service are the GP Surgery Visits, 
Practice Nurse and District Nurse visits. This will no doubt vary from centre to centre based on 
local practice.  Lymphoedema Network Wales uses a system of a one-stop clinic compared with 
usual care in the other health boards. This is different to other local services and we suggest the 
differences between the services needs to be explored further. 
Conclusion 
The evaluation of cancer-related Lymphoedema treatment programmes (Shih, et al., 2009; 
Stout, et al., 2013; Stout, et al 2012) and the possible consequential post treatment economic 
burden provides an excellent scenario for illustrating the complexities involved in attempting to 
integrate the evidence relating to rehabilitation effectiveness and resource utilisation. 
Therefore, further cost analysis research is needed to estimate the economic burden of these 
patients on the NHS and social services within the UK and thus evidence is welcomed and 
needed to prove whether this can have an impact on current public health policies. This 
evaluation indicates a considerable cost burden of lymphoedema to NHS Wales and provides 
estimation of the potential for cost saving when people with lymphoedema are managed within 
lymphoedema services rather than undiagnosed/misdiagnosed frequent users of both primary 
and secondary care.  
Further work by the Lymphoedema Network Wales will be able to capitalise on this evaluation 
to provide on-going evidence of the ’real- world’ economic impact of the service alongside all 
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other aspects of delivery which exemplify this service as a model of prudent health care 
(Aylward, et al., 2013, Drakeford 2014; Bradley, Wilson, et al., 2014). 
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